Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Prescient’s technologies emanate from prestigious world class centres including Yale, Penn, Oxford and Moffitt.
Targeted therapy:
Prescient’s first in class targeted therapy – PTX-100 – is currently in clinical development and showing encouraging activity in diseases of unmet need.
Cell therapies:
Prescient owns the exclusive rights to two next-generation cell therapy platform technologies, OmniCAR and CellPryme – both with the potential to enhance CAR-T therapies and overcome challenges faced by current generation approaches
Company Details
- Employees
- 14
- Founded
- 2014
- Address
- Level 11, 385 Bourke Street, Suite 2,australia
- Phone
- 61396927222
- ju****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- prescienttherapeutics.com
- Keywords
- Representative jobs.
- HQ
- Melbourne, Victoria
Prescient Therapeutics Questions
Prescient Therapeutics's helpline number is 61396927222
Prescient Therapeutics's website is prescienttherapeutics.com
Prescient Therapeutics's LinkedIn profile is https://au.linkedin.com/company/prescient-therapeutics
Prescient Therapeutics has
14 employees.
View email and phone details for 14
employees at Prescient Therapeutics.
Prescient Therapeutics's industry is
Biotechnology Research
Prescient Therapeutics's top competitors are
Paradigm Biopharmaceuticals,
Chimeric Therapeutics,
Noxopharm Limited,
Audax Biosciences,
Cynata Therapeutics,
Telix Pharmaceuticals Limited,
Cartherics Pty Ltd,
Carina Biotech,
Myrio Tx,
Imugene Limited.
Prescient Therapeutics's support email address is justin@ptxtherapeutics.com
Prescient Therapeutics's categories are Biotechnology Research
Prescient Therapeutics's founding year is 2014
